GlassScriptPhysician profile
Laurel Rae Zuberi
NPI 1457395311
$10,907.73
in general payments reported to CMS, 2019-2025
45 companies · $2,677 in 2025
The $2,677 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,350 · 2022: $2,302 · 2023: $2,277 · 2024: $2,302 · 2025: $2,677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,255.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,326.47 | 2021-2025 | Evenity, Prolia, Tepezza |
| Novo Nordisk INC | $1,292.55 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $920.55 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $655.47 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $652.95 | 2021-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $624.76 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Dexcom, INC. | $603.11 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $545.27 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $526.00 | 2021-2025 | |
| Corcept Therapeutics | $400.15 | 2021-2025 | Korlym |
| Medtronic, INC. | $362.68 | 2021-2025 | Minimed 780g |
| Tandem Diabetes Care, INC. | $269.77 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals LP | $247.13 | 2021-2025 | Farxiga |
| Alexion Pharmaceuticals, INC. | $239.11 | 2022-2025 | Strensiq |
| Sanofi-Aventis U.S. LLC | $176.02 | 2021-2024 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amphastar Pharmaceuticals, INC. | $159.71 | 2023-2025 | Baqsimi |
| Abbvie INC. | $143.10 | 2021-2025 | |
| Amryt Pharma Holdings LTD | $140.39 | 2022 | |
| Nevro Corp. | $139.17 | 2021-2023 | Senza |
| Horizon Therapeutics Plc | $126.74 | 2021-2023 | Tepezza |
| Recordati_rare_diseases_inc. | $122.67 | 2021-2024 | Signifor Lar, Isturisa |
| Neurocrine Biosciences, INC. | $115.26 | 2025 | |
| Insulet Corporation | $113.06 | 2024-2025 | Omnipod |
| Ascensia Diabetes Care US INC. | $112.81 | 2021-2024 | |
| Zealand Pharma US, INC. | $108.83 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $94.07 | 2025 | Yorvipath |
| Pfizer INC. | $76.26 | 2022-2023 | |
| Sandoz INC. | $56.54 | 2025 | Jubbonti |
| Esperion Therapeutics, INC. | $52.38 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $51.72 | 2021-2023 | Steglatro |
| Radius Health, INC. | $49.86 | 2022-2024 | Tymlos |
| Chiasma, INC. | $46.99 | 2021 | |
| Madrigal Pharmaceuticals | $46.31 | 2025 | Rezdiffra |
| Eusa Pharma (US) LLC | $41.98 | 2022 | |
| Mannkind Corporation | $41.47 | 2021 | |
| Beta Bionics, INC. | $36.40 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ultragenyx Pharmaceutical INC. | $33.83 | 2021 | |
| Clarus Therapeutics INC. | $24.15 | 2021 | |
| Roche Diabetes Care, INC. | $23.78 | 2021 | |
| Sequel Med Tech, LLC | $22.33 | 2025 | Twiist |
| Lifescan, INC. | $20.38 | 2021 | |
| Ibsa Pharma INC. | $18.05 | 2021 | |
| Grt US Holding, INC. | $17.91 | 2022 | |
| Tersera Therapeutics LLC | $15.04 | 2023 | Xermelo |
| Amarin Pharma, INC. | $14.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurel Zuberi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.